Krystal Biotech Inc (KRYS)

Working capital turnover

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Revenue (ttm)	US$ in thousands	102,227	56,573	9,365	809	809	0	0	0	0	0	0	0	0	0	0	0	542	1,125	1,342	1,515
Total current assets	US$ in thousands	602,248	587,909	582,128	484,004	355,429	383,779	397,578	428,770	437,998	442,267	345,812	369,927	405,826	275,058	287,652	298,539	188,329	195,880	204,435	196,203
Total current liabilities	US$ in thousands	47,589	33,094	27,583	23,898	35,076	28,847	28,032	34,427	60,437	25,736	35,779	18,119	9,144	15,452	7,198	5,831	4,061	3,327	3,726	3,940
Working capital turnover		0.18	0.10	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.01

March 31, 2024 calculation

Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $102,227K ÷ ($602,248K – $47,589K)
= 0.18

The working capital turnover ratio for Krystal Biotech Inc has shown a significant improvement over the recent quarters. The ratio increased from 0.01 in June 2019 to 0.18 in March 2024, indicating a more efficient management of working capital during this period.

A working capital turnover ratio of 0.18 in March 2024 suggests that Krystal Biotech Inc generated $0.18 in revenue for every dollar of working capital invested in the business during that quarter. This signifies an ability to efficiently utilize its working capital to support its operations and generate sales.

The trend of steadily increasing working capital turnover ratios over the quarters since June 2019 reflects positively on the company's operational efficiency and effectiveness in managing its current assets and liabilities. A higher working capital turnover ratio generally indicates better efficiency, as the company is able to generate more revenue with less investment in working capital.

Overall, the improving trend in Krystal Biotech Inc's working capital turnover ratio suggests that the company has been optimizing its working capital management practices, which can lead to enhanced profitability and operational performance in the future.